Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2014

Open Access 01-12-2014 | Research

TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families

Authors: Nathalia M Cury, Victor EF Ferraz, Wilson A Silva Jr

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2014

Login to get access

Abstract

Background

Approximately 5-10% of breast cancers are hereditary. Among hereditary syndromes, Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Li-Fraumeni Syndrome (LFS) have received the most attention. HBOC is due to mutations in the BRCA1 and BRCA2 genes and is characterized by breast adenocarcinoma and/or epithelial ovarian carcinoma. LFS is associated with germline mutations in TP53; the most frequent cancer types associated with this syndrome are sarcoma, breast cancer, leukemia, brain tumors and adrenocortical carcinomas. Other cancers related to LFS are found at lower frequencies. In Brazil, especially in the southern part of the country, a specific mutation in the TP53 gene, TP53 p.R337H, occurs at a high frequency in childhood adrenocortical tumors. It has been proposed that this mutation increases breast cancer risk in southern Brazilian women.

Methods

We carried out a case-control study to determine the prevalence of the TP53 p.R337H mutation in 28 female cancer patients attended at the Cancer Genetic Counseling Service of the General Hospital of the University of São Paulo Medical School of Ribeirão Preto who fulfilled Hereditary Breast and Ovary Cancer Syndrome genetic test criteria compared to healthy woman (controls). TP53 p.R337H mutation status was determined using the High Resolution Melting (HRM) method, followed by DNA sequencing. Fisher’s test was used to compare the prevalence of TP53 p.R337H in the patient and control groups.

Results

Two of the breast cancer cases (7.1%) and none of the controls carried the TP53 p.R337H mutation. At the time of the investigation, both cases fulfilled testing criteria for Hereditary Breast and Ovary Cancer Syndrome but not Li-Fraumeni or Li-Fraumeni-like Syndrome, based on genetic testing criteria of NCCN Clinical Practice Guidelines in Oncology (v.1.2010).

Conclusions

We suggest that genetic screening of Brazilian breast cancer patients who fulfill Hereditary Breast and Ovary Cancer Syndrome criteria and have a family history that includes other tumors of the LFS/LFL spectrum be tested for the TP53 p.R337H mutation.
Appendix
Available only for authorised users
Literature
2.
go back to reference INCA. National Cancer InstituteMinistry of Health. Department of Health Care Coordination for Prevention and Surveillance. Estimate 2012. Rio de Janeiro: Cancer Incidence in Brazil; INCA. National Cancer InstituteMinistry of Health. Department of Health Care Coordination for Prevention and Surveillance. Estimate 2012. Rio de Janeiro: Cancer Incidence in Brazil;
3.
go back to reference Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 1996,77(11):2318–2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-ZCrossRefPubMed Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 1996,77(11):2318–2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-ZCrossRefPubMed
4.
go back to reference Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006,295(12):1379–1388. 10.1001/jama.295.12.1379CrossRefPubMed Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006,295(12):1379–1388. 10.1001/jama.295.12.1379CrossRefPubMed
6.
go back to reference Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011,5(1):5–23. 10.1016/j.molonc.2010.11.003CrossRefPubMed Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011,5(1):5–23. 10.1016/j.molonc.2010.11.003CrossRefPubMed
7.
go back to reference Schneider K: Counseling about cancer: strategies for genetic counseling. 2nd edition. New York: Wiley-Liss; 2002. Schneider K: Counseling about cancer: strategies for genetic counseling. 2nd edition. New York: Wiley-Liss; 2002.
8.
go back to reference Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990,250(4985):1233–1238. 10.1126/science.1978757CrossRefPubMed Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990,250(4985):1233–1238. 10.1126/science.1978757CrossRefPubMed
9.
go back to reference Li FP, e Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969,71(4):747–752. 10.7326/0003-4819-71-4-747CrossRefPubMed Li FP, e Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969,71(4):747–752. 10.7326/0003-4819-71-4-747CrossRefPubMed
10.
go back to reference Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001,10(2):83–87.PubMed Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001,10(2):83–87.PubMed
11.
go back to reference Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994,54(5):1298–1304.PubMed Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994,54(5):1298–1304.PubMed
12.
go back to reference Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995, 25: 101–124.PubMed Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995, 25: 101–124.PubMed
13.
go back to reference Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000,82(12):1932–1937.CrossRefPubMedPubMedCentral Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000,82(12):1932–1937.CrossRefPubMedPubMedCentral
14.
go back to reference NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology TM. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Li-Fraumeni Syndrome (LIFR-1). V.4; 2013. http://www.nccn.org NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology TM. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Li-Fraumeni Syndrome (LIFR-1). V.4; 2013. http://​www.​nccn.​org
15.
go back to reference Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH: Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012,14(2):R66. 10.1186/bcr3172CrossRefPubMedPubMedCentral Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH: Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012,14(2):R66. 10.1186/bcr3172CrossRefPubMedPubMedCentral
16.
go back to reference Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC: Impact of Neonatal Screening and Surveillance for the TP53 TP53 P.R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013,31(20):2619–2626. 10.1200/JCO.2012.46.3711CrossRefPubMedPubMedCentral Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC: Impact of Neonatal Screening and Surveillance for the TP53 TP53 P.R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013,31(20):2619–2626. 10.1200/JCO.2012.46.3711CrossRefPubMedPubMedCentral
17.
go back to reference Achatz MI, Olivier M, le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, da Rocha JC, Vettore AL, Hainaut P: The TP53 mutation, TP53 P.R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007,245(1–2):96–102.CrossRefPubMed Achatz MI, Olivier M, le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, da Rocha JC, Vettore AL, Hainaut P: The TP53 mutation, TP53 P.R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007,245(1–2):96–102.CrossRefPubMed
18.
go back to reference Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA: Association of the germline TP53 TP53 P.R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008, 8: 357. 10.1186/1471-2407-8-357CrossRefPubMedPubMedCentral Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA: Association of the germline TP53 TP53 P.R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008, 8: 357. 10.1186/1471-2407-8-357CrossRefPubMedPubMedCentral
19.
go back to reference Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI: Detailed haplotype analysis at the TP53 locus in p.TP53 P.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010,31(2):143–150. 10.1002/humu.21151CrossRefPubMed Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI: Detailed haplotype analysis at the TP53 locus in p.TP53 P.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010,31(2):143–150. 10.1002/humu.21151CrossRefPubMed
20.
go back to reference Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P: Detection of TP53 P.R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008,261(1):21–25. 10.1016/j.canlet.2007.10.044CrossRefPubMed Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P: Detection of TP53 P.R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008,261(1):21–25. 10.1016/j.canlet.2007.10.044CrossRefPubMed
21.
go back to reference NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Hereditary Breast and/or Ovarian Cancer (HBOC-1) V.1; 2010. http://www.nccn.org NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Hereditary Breast and/or Ovarian Cancer (HBOC-1) V.1; 2010. http://​www.​nccn.​org
22.
go back to reference Bastien R, Lewis TB, Hawkes JE, Quackenbush JF, Robbins TC, Palazzo J, Perou CM, Bernard PS: High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat 2008,29(5):757–764. 10.1002/humu.20726CrossRefPubMed Bastien R, Lewis TB, Hawkes JE, Quackenbush JF, Robbins TC, Palazzo J, Perou CM, Bernard PS: High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat 2008,29(5):757–764. 10.1002/humu.20726CrossRefPubMed
23.
go back to reference de Leeneer K, Coene I, Poppe B, de Paepe A, Claes K: Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clin Chem 2008,54(6):982–989. 10.1373/clinchem.2007.098764CrossRefPubMed de Leeneer K, Coene I, Poppe B, de Paepe A, Claes K: Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clin Chem 2008,54(6):982–989. 10.1373/clinchem.2007.098764CrossRefPubMed
24.
go back to reference Keshavarzi F, Javadi GR, Zeinali S: BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 2012,11(1):57–67. 10.1007/s10689-011-9477-3CrossRefPubMed Keshavarzi F, Javadi GR, Zeinali S: BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 2012,11(1):57–67. 10.1007/s10689-011-9477-3CrossRefPubMed
25.
go back to reference Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988,48(18):5358–5362.PubMed Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988,48(18):5358–5362.PubMed
26.
go back to reference Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009,27(26):e108-e109. author reply e110 10.1200/JCO.2009.22.7967CrossRefPubMed Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009,27(26):e108-e109. author reply e110 10.1200/JCO.2009.22.7967CrossRefPubMed
27.
go back to reference Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001,86(10):4970–4973. 10.1210/jcem.86.10.7957CrossRefPubMed Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001,86(10):4970–4973. 10.1210/jcem.86.10.7957CrossRefPubMed
28.
go back to reference Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC: Penetrance of adrenocortical tumours associated with the germline TP53 TP53 P.R337H mutation. J Med Genet 2006,43(1):91–96.CrossRefPubMed Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC: Penetrance of adrenocortical tumours associated with the germline TP53 TP53 P.R337H mutation. J Med Genet 2006,43(1):91–96.CrossRefPubMed
29.
go back to reference Digiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW: A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002,9(1):12–16. 10.1038/nsb730CrossRefPubMed Digiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW: A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002,9(1):12–16. 10.1038/nsb730CrossRefPubMed
30.
go back to reference Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A, Pitombo MB, Leal PR F, Royer R, Zhang P, Narod SA: The TP53 P.R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012,10(1):3. 10.1186/1897-4287-10-3CrossRefPubMedPubMedCentral Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A, Pitombo MB, Leal PR F, Royer R, Zhang P, Narod SA: The TP53 P.R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012,10(1):3. 10.1186/1897-4287-10-3CrossRefPubMedPubMedCentral
31.
go back to reference Mccuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D: Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012,11(4):607–613. 10.1007/s10689-012-9557-zCrossRefPubMed Mccuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D: Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012,11(4):607–613. 10.1007/s10689-012-9557-zCrossRefPubMed
Metadata
Title
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families
Authors
Nathalia M Cury
Victor EF Ferraz
Wilson A Silva Jr
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2014
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-12-8

Other articles of this Issue 1/2014

Hereditary Cancer in Clinical Practice 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine